Try our beta test site
397 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
21 Temporarily not available HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option
Condition: Anemia
Intervention: Drug: HBOC-201
22 Available Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Condition: Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven IV lipid emulsion
23 Available Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
Condition: Parenteral Nutrition-Associated Liver Disease
Intervention: Drug: Omegaven
24 Available cliniMACs HUD for T Cell Depletion
Condition: x Linked Combined Immunodeficiency
Intervention: Device: CliniMACs
25 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban
26 Available A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers
Condition: Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer
Intervention: Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
27 Approved for marketing Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance.
Condition: Chronic Renal Failure
Intervention: Other: intradialytic physical training program
28 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
29 Available Early Patient Access Treatment Use Protocol CA204-220
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
30 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
31 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
32 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
33 Available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
34 Available Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder;   Epstein-Barr Virus-Associated Viremia
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs)
35 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
36 Available Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Abemaciclib
37 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib
38 Available Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Conditions: Cholestasis;   Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven
39 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
40 Available Effect of Low Level Laser Therapy on Endometrial Cells: An In Vitro Study
Condition: Infertility
Intervention: Device: Low level Laser diode machine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.